Renee Benghozi

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Red Blood Cell Membrane Cholesterol May Be a Key Regulator of Sickle Cell Disease Microvascular Complications.

Red Blood Cell Membrane Cholesterol May Be a Key Regulator of Sickle Cell Disease Microvascular Complications.

Journal: Membranes

Published: October 20, 2022

Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings.

Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings.

Journal: Clinical drug investigation

Published: February 19, 2017

Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease.

Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease.

Journal: Cardiovascular drugs and therapy

Published: December 02, 2015

Potential Signal Transduction Regulation by HDL of the β2-Adrenergic Receptor Pathway. Implications in Selected Pathological Situations.

Potential Signal Transduction Regulation by HDL of the β2-Adrenergic Receptor Pathway. Implications in Selected Pathological Situations.

Journal: Archives of medical research

Published: April 27, 2015

Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.

Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein.

Journal: Cardiovascular drugs and therapy

Published: March 10, 2015

First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin.

First-in-Man Study With Inclacumab, a Human Monoclonal Antibody Against P-selectin.

Journal: Journal of cardiovascular pharmacology

Published: February 26, 2015

Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.

Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.

Journal: Vascular pharmacology

Published: February 11, 2015

Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?

Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy?

Journal: Journal of clinical lipidology

Published: December 03, 2014

Biological variation of established and novel biomarkers for atherosclerosis: Results from a prospective, parallel-group cohort study.

Biological variation of established and novel biomarkers for atherosclerosis: Results from a prospective, parallel-group cohort study.

Journal: Clinica chimica acta; international journal of clinical chemistry

Published: November 02, 2014

Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.

Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.

Journal: Heart (British Cardiac Society)

Published: August 22, 2014

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.

Journal: Circulation. Cardiovascular genetics

Published: May 06, 2014

Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study.

Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study.

Journal: Lipids

Published: June 25, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026